Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2026)
Recursion Pharmaceuticals (RXRX) reported Gross Margin of 92.99% for Q1 2026, down 4494.0% on a YoY basis from 2.12% in Q1 2025, and down 255.41% quarter-over-quarter from 59.83% in Q4 2025.
Recursion Pharmaceuticals (RXRX) Gross Margin (2021 - 2026) Analysis & Trends
Recursion Pharmaceuticals has reported Gross Margin for 6 years, with the latest figure at 92.99% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin fell 4494.0% year-over-year to 92.99%; the trailing twelve-month figure through Mar 2026 stood at 7.22% (up 72.0% YoY), and the FY2025 full-year result was 4.99%, down 1812.0% from the prior year.
- Gross Margin for Q1 2026 stood at 92.99%, down from 59.83% in the prior quarter.
- The five-year high for Gross Margin was 59.83% in Q4 2025, with the low at 183.81% in Q3 2025.
- Historically, Gross Margin has averaged 26.59% across 5 years, with a median of 3.27% in 2023.
- The largest YoY upside for Gross Margin was 24127 bps in 2025 against a maximum downside of 23750 bps in 2025.
- Recursion Pharmaceuticals' Gross Margin stood at 20.74% in 2022, then sank by 55 bps to 9.27% in 2023, then sank by 2056 bps to 181.43% in 2024, then jumped by 133 bps to 59.83% in 2025, then tumbled by 255 bps to 92.99% in 2026.
- The last three Gross Margin figures came in at 92.99% (Q1 2026), 59.83% (Q4 2025), and 183.81% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -92.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.99% |
| Dec 31, 2025 | 59.83% |
| Sep 30, 2025 | -183.81% |
| Jun 30, 2025 | -4.88% |
| Mar 31, 2025 | -48.04% |
| Dec 31, 2024 | -181.43% |
| Sep 30, 2024 | 53.69% |
| Jun 30, 2024 | 36.19% |
| Mar 31, 2024 | 19.05% |
| Dec 31, 2023 | 9.27% |
| Sep 30, 2023 | -3.27% |
| Jun 30, 2023 | 14.84% |
| Mar 31, 2023 | -2.59% |
| Dec 31, 2022 | 20.74% |
| Sep 30, 2022 | -17.09% |
| Jun 30, 2022 | -85.39% |
| Mar 31, 2022 | -46.24% |
| Dec 31, 2021 | 100.00% |
| Sep 30, 2021 | 100.00% |
| Jun 30, 2021 | 100.00% |